THE FIRST AND ONLY PROVEN ALTERNATIVE TO AUTOGRAFT IN ANKLE AND HINDFOOT ARTHRODESIS
- Level 1 evidence from largest F&A clinical trial ever conducted
- Equivalent improvements in clinical outcomes, compared to the gold standard autograft1
- Class III combination product labeled for ankle and hindfoot arthrodesis
- Bioengineered human PDGF-BB stimulates multiple aspects of healing in response to injury
- rhPDGF-BB is highly purified with consistent biological potency; allograft and autograft are highly variable in quality and potency2,3,4,5
- In commercial use since 2009 (Canada)
- Eliminates risks, morbidities, costs associated with autograft harvest
1. DiGiovanni, et al. JBJS (2013).
2. Fiedler, et al. J Cell Biochem (2002).
3. Ozaki, et al. J Stem Cells & Dev (2007).
4. Bouletreau, et al. Plast Reconstr Surg (2002).
5. Hollinger, et al. JBJS (2008).
For reimbursement information, visit www.wright.com/reimbursement.